Welcome!

News Feed Item

Neuromodulation Market - [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] - Forecasts to 2017

NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017

http://www.reportlinker.com/p01083659/Neuromodulation-Market-–-[Spinal-Cord-Stimulation-SCS-Vagus-Nerve-Stimulation-VNS-Gastric-Electrical-Stimulation-GES-Deep-Brain-Stimulation-DBS-Sacral-Nerve-Stimulation-SNS--Transcranial-Magnetic-Stimulation-TMS]-–-Forecasts-to-2017 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non–invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS).

The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder.

The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer's, epilepsy, spinal cord injury, and Parkinson's disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S.

This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation.

The key players in the neuromodulation devices market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.).

Scope of the Report

The research report categorizes the global neuromodulation devices market by procedure, technology, and application. These markets are broken down into segments and sub-segments, providing exhaustive value-volume analysis for 2010, 2011, and 2012 as well as forecast up to 2017. Each market is also analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World to provide in-depth information on the global scenario.

Global Neurostimulation Devices Market, by Procedure:

Internal Neurostimulation

Spinal Cord Stimulation (SCS)

Failed Back Surgery Syndrome

Chronic Pain

Ischemic Pain

Others

Deep Brain Stimulation (DBS)

Movement Disorders

Parkinson's Disease

Alzheimer's Disease

Dystonia

Tourette's Syndrome

Others

Chronic Pain

Depression

Post-Traumatic Coma

Sacral Nerve Stimulation (SNS)

Urine Incontinence

Fecal Incontinence

Vagus Nerve Stimulation (VNS)

Epilepsy disease

Heart Failure

Tinnitus

Others

Gastric Electrical Stimulation (GES)

Gastroparesis

Others

External Neurostimulation

Transcranial Magnetic Stimulation (TMS)

Depression

Tinnitus

Migraine

Stroke

Others

Transcutaneous Electrical Nerve Stimulation (TENS)

Global Neurostimulation Devices Market, by Geography

North AmericaEuropeAsia-PacificRest of the World

TABLE OF CONTENTS

1 INTRODUCTION 16

1.1 KEY TAKE-AWAYS 16

1.2 REPORT DESCRIPTION 16

1.3 MARKETS COVERED 18

1.4 RESEARCH METHODOLOGY 20

1.4.1 MARKET SIZE 20

1.4.2 MARKET SHARE 20

1.4.3 KEY DATA POINTS FROM SECONDARY SOURCES 20

1.4.4 KEY DATA POINTS FROM PRIMARY SOURCES 21

1.4.5 ASSUMPTIONS 21

1.5 STAKEHOLDERS 21

2 EXECUTIVE SUMMARY 22

3 MARKET OVERVIEW 25

3.1 INTRODUCTION 26

3.2 MARKET SEGMENTATION 27

3.3 MARKET DYNAMICS 29

3.3.1 DRIVERS 29

3.3.1.1 Increasing incidence of neurological disorders to spur market growth 29

3.3.1.2 Unprecedented global aging to fuel market growth 29

3.3.1.3 Strong product pipeline to propel the market 30

3.3.1.4 Expanded target applications and new indications are expected to stimulate growth of neuromodulation devices 30

3.3.1.5 Investments and funds – an impetus for market growth 31

3.4 RESTRAINTS 32

3.4.1.1 An unfavourable reimbursement scenario hinders market growth 32

3.4.1.2 Lack of trained professionals likely to hamper market growth 33

3.5 MARKET SHARE ANALYSIS 33

4 GLOBAL NEUROMODULATION MARKET (INTERNAL & EXTERNAL) 35

4.1 INTRODUCTION 36

4.2 INTERNAL STIMULATION 37

4.2.1 SPINAL CORD STIMULATION (SCS) MARKET 37

4.2.1.1 Major applications 39

4.2.1.1.1 Failed back surgery syndrome 40

4.2.1.1.2 Chronic pain 40

4.2.1.1.3 Ischemia 42

4.2.2 DEEP BRAIN STIMULATION (DBS) 42

4.2.2.1 Major applications 45

4.2.2.1.1 Parkinson's disease 46

4.2.2.1.2 Dystonia 47

4.2.2.1.3 Tremor 47

4.2.2.1.4 Alzheimer's 48

4.2.3 SACRAL NERVE STIMULATION (SNS) 48

4.2.3.1 Major applications 51

4.2.3.1.1 Urine incontinence 52

4.2.3.1.2 Fecal incontinence 53

4.2.4 VAGUS NERVE STIMULATION (VNS) 53

4.2.4.1 Major applications 56

4.2.4.1.1 Epilepsy 57

4.2.4.1.2 Others 58

4.2.5 GASTRIC ELECTRICAL STIMULATION (GES) 58

4.3 EXTERNAL STIMULATION 61

4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) 61

4.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) 64

5 GEOGRAPHIC ANALYSIS 685.1 INTRODUCTION 695.2 NORTH AMERICA 725.3 EUROPE 805.4 ASIA 875.5 REST OF THE WORLD 976 COMPETITIVE LANDSCAPE 1066.1 INTRODUCTION 1066.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES 1086.3 NEW PRODUCT LAUNCH 1106.4 EXPANSION 1126.5 OTHER DEVELOPMENTS 1136.6 APPROVALS 1147 COMPANY PROFILES 122(Overview, Financials, Products & Services, Strategy, & Developments)*7.1 ANM ADAPTIVE NEUROMODULATION GMBH 1227.2 BIOCONTROL MEDICAL, LTD. 1257.3 BOSTON SCIENTIFIC CORPORATION 1287.4 CERBOMED GMBH 1367.5 CYBERONICS, INC. 1397.6 ENDOSTIM, INC. 1447.7 ENTEROMEDICS, INC. 1477.8 THE MAGSTIM COMPANY LIMITED 1507.9 MEDTRONIC, INC. 1537.10 NEURONETICS, INC. 1597.11 NEUROPACE, INC. 1627.12 NEUROSIGMA, INC. 1647.13 NEVRO CORPORATION 1677.14 RS MEDICAL 1697.15 SPINAL MODULATION, INC. 1727.16 ST. JUDE MEDICAL 1747.17 SYNAPSE BIOMEDICAL, INC. 1827.18 UROPLASTY, INC. 1847.19 ZYNEX, INC. 188*Details on financials, product & services, strategy, and developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 GLOBAL NEUROMODULATION MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 23TABLE 2 GLOBAL NEUROMODULATION MARKET, BY MODALITY,2010 – 2017 ($MILLION) 23TABLE 3 SPINAL CORD STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 38TABLE 4 SPINAL CORD STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 39TABLE 5 GLOBAL SPINAL CORD STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 41TABLE 6 DEEP BRAIN STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 44TABLE 7 DEEP BRAIN STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010-2017 (NO OF UNITS) 45TABLE 8 GLOBAL DEEP BRAIN STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 46TABLE 9 SACRAL NERVE STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 50TABLE 10 SACRAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 51TABLE 11 GLOBAL SACRAL NERVE STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 52TABLE 12 VAGUS NERVE STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 55TABLE 13 VAGUS NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS) 56TABLE 14 GLOBAL VAGUS NERVE STIMULATION MARKET, BY APPLICATION,2010 – 2017 ($MILLION) 57TABLE 15 GASTRIC ELECTRICAL STIMULATION MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 59TABLE 16 GASTRIC ELECTRICAL STIMULATION MARKET VOLUME,BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 60TABLE 17 GLOBAL GASTRIC ELECTRICAL STIMULATION MARKET,BY APPLICATION, 2010-2017 ($MILLION) 61TABLE 18 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET,BY GEOGRAPHY, 2010 – 2017($MILLION) 63TABLE 19 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 64TABLE 20 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 65TABLE 21 TRANSCRANIAL MAGNETIC STIMULATION MARKET VOLUME,BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS) 66TABLE 22 GLOBAL TRANSCRANIAL MAGNETIC STIMULATION MARKET,BY APPLICATION, 2010 – 2017 ($MILLION) 67TABLE 23 NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION) 69TABLE 24 EXTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 70TABLE 25 INTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 71TABLE 26 GLOBAL EXTERNAL NEUROMODULATION MARKET, BY MODALITY,2010 – 2017 ($MILLION) 71TABLE 27 GLOBAL EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO OF UNITS) 72TABLE 28 NORTH AMERICA: NEUROMODULATION DEVICES MARKET,BY PROCEDURE, 2010 – 2017 ($MILLION) 73TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 74TABLE 30 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 75TABLE 31 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 75TABLE 32 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 76TABLE 33 NORTH AMERICA: SPINAL CORD STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 76TABLE 34 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 77TABLE 35 NORTH AMERICA: SACRAL NERVE STIMULATION, BY COUNTRY,2010 – 2017 ($MILLION) 77TABLE 36 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 78TABLE 37 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 78TABLE 38 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79TABLE 39 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 79TABLE 40 EUROPE: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 81TABLE 41 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 81TABLE 42 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 82TABLE 43 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 83TABLE 44 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS) 83TABLE 45 EUROPE: SPINAL CORD STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 84TABLE 46 EUROPE: DEEP BRAIN STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 84TABLE 47 EUROPE: SACRAL NERVE STIMULATION, BY REGION,2010 – 2017 ($MILLION) 85TABLE 48 EUROPE: VAGUS NERVE STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 85TABLE 49 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 86TABLE 50 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET,BY REGION, 2010 – 2017 ($MILLION) 86TABLE 51 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 87TABLE 52 ASIA: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 88TABLE 53 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 89TABLE 54 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 90TABLE 55 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 90TABLE 56 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 91TABLE 57 ASIA: SPINAL CORD STIMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 92TABLE 58 ASIA: DEEP BRAIN STIMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 93TABLE 59 ASIA: SACRAL NERVE STIMULATION, BY COUNTRY,2010 – 2017 ($MILLION) 94TABLE 60 ASIA: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 95TABLE 61 ASIA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 96TABLE 62 ROW: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION) 97TABLE 63 ROW: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION) 98TABLE 64 ROW: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 99TABLE 65 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION) 99TABLE 66 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS) 100TABLE 67 ROW: SPINAL CORD STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 100TABLE 68 ROW: DEEP BRAIN STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 101TABLE 69 ROW: SACRAL NERVE STIMULATION, BY REGION,2010 – 2017 ($MILLION) 102TABLE 70 ROW: VAGUS NERVE STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 102TABLE 71 ROW: GASTRIC ELECTRICAL STIMULATION MARKET, BY REGION,2010 – 2017 ($MILLION) 103TABLE 72 ROW: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 104TABLE 73 ROW: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION) 104TABLE 74 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES, 2010 – 2012 108TABLE 75 NEW PRODUCT LAUNCH, 2010 – 2012 110TABLE 76 EXPANSION, 2010 – 2012 112TABLE 77 OTHER DEVELOPMENTS, 2010 – 2012 113TABLE 78 APPROVALS, 2010 – 2012 114TABLE 79 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 129TABLE 80 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION) 129TABLE 81 BOSTON SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 130TABLE 82 CYBERONICS, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 140TABLE 83 CYBERONICS, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 140TABLE 84 MEDTRONIC, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 154TABLE 85 MEDTRONIC, INC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 154TABLE 86 MEDTRONIC, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 155TABLE 87 ST. JUDE MEDICAL, INC: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION) 175TABLE 88 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 175TABLE 89 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 176TABLE 90 UROPLASTY, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2010-2012 ($MILLION) 185TABLE 91 UROPLASTY, INC.: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION) 185TABLE 92 ZYNEX, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION) 189TABLE 93 ZYNEX, INC.: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION) 189

LIST OF FIGURES

FIGURE 1 NEUROMODULATION MARKET SEGMENTATION 28FIGURE 2 MARKET DYNAMICS 32FIGURE 3 NEUROMODULATION MARKET SHARE ANALYSIS, BY REVENUE, 2011 34FIGURE 4 KEY GROWTH STRATEGIES, 2010 – 2012 107

To order this report: Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Modern software design has fundamentally changed how we manage applications, causing many to turn to containers as the new virtual machine for resource management. As container adoption grows beyond stateless applications to stateful workloads, the need for persistent storage is foundational - something customers routinely cite as a top pain point. In his session at @DevOpsSummit at 21st Cloud Expo, Bill Borsari, Head of Systems Engineering at Datera, explored how organizations can reap the bene...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and G...
"DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great team at @DevOpsSUMMIT and CloudEXPO tell the world how they can leverage this emerging disruptive trend."
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
You want to start your DevOps journey but where do you begin? Do you say DevOps loudly 5 times while looking in the mirror and it suddenly appears? Do you hire someone? Do you upskill your existing team? Here are some tips to help support your DevOps transformation. Conor Delanbanque has been involved with building & scaling teams in the DevOps space globally. He is the Head of DevOps Practice at MThree Consulting, a global technology consultancy. Conor founded the Future of DevOps Thought Leade...
DXWorldEXPO LLC announced today that ICC-USA, a computer systems integrator and server manufacturing company focused on developing products and product appliances, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of ...
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
Everyone wants the rainbow - reduced IT costs, scalability, continuity, flexibility, manageability, and innovation. But in order to get to that collaboration rainbow, you need the cloud! In this presentation, we'll cover three areas: First - the rainbow of benefits from cloud collaboration. There are many different reasons why more and more companies and institutions are moving to the cloud. Benefits include: cost savings (reducing on-prem infrastructure, reducing data center foot print, redu...
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
The technologies behind big data and cloud computing are converging quickly, offering businesses new capabilities for fast, easy, wide-ranging access to data. However, to capitalize on the cost-efficiencies and time-to-value opportunities of analytics in the cloud, big data and cloud technologies must be integrated and managed properly. Pythian's Director of Big Data and Data Science, Danil Zburivsky will explore: The main technology components and best practices being deployed to take advantage...